Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa, et al. Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan. Current oncology (Toronto, Ont.). 2024. 31. 12. 7914-7923
Makoto Kawase, Keita Nakane, Koji Iinuma, Kota Kawase, Tomoki Taniguchi, Masayuki Tomioka, Yuki Tobisawa, Takuya Koie. Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review. Journal of clinical medicine. 2024. 13. 18
中根 慶太, 川瀬 真, 川瀬 紘太, 飯沼 光司, 古家 琢也. 【ロボット支援手術におけるNightmareとその対策】当科で経験した重篤なRARC術後合併症の2例. Japanese Journal of Endourology and Robotics. 2024. 37. 2. 296-303
Takuya Koie, Keita Nakane, Koji Iinuma. Editorial Comment from Dr Koie et al. to Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy. International Journal of Urology. 2020. 27. 7. 623
Changes in lower urinary tract symptoms after more than five years of follow-up in a cohorts of prostate cancer treated by permanent iodine-125 implant brachytherapy.
(International Continence Society 49th Annual Meeting. 2019)
Hemorrhoid as a risk factor for rectal bleeding after permanent Iodine-125 brachytherapy for prostate cancer.
(38th Congress of the Societe Internationale d’Urologie. 2018)
Significance of random bladder biopsy in initially diagnosed superficial bladder cancer.
(37th Congress of the Societe Internationale d’Urologie. 2017)